Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

[1]  B. Gusterson,et al.  High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Andersson,et al.  S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. , 1994, British Journal of Cancer.

[3]  G. Calais,et al.  Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm , 1994, Cancer.

[4]  C. Gillett,et al.  The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. , 1994, British Journal of Cancer.

[5]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[6]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[7]  H. Magdelenat,et al.  Prognostic Value of the S‐Phase Fraction of Breast Cancers Treated by Primary Radiotherapy or Neoadjuvant Chemotherapy , 1993, Annals of the New York Academy of Sciences.

[8]  J. Foekens,et al.  Prognostic factors and response to therapy in breast cancer. , 1993, Cancer surveys.

[9]  C. Wolf,et al.  Over‐expression of P‐glycoprotein and glutathione S‐transferase PI in MCF‐7 cells selected for vincristine resistance in vitro , 1992, International journal of cancer.

[10]  P Boracchi,et al.  Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Osborne,et al.  HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Y. Bignon,et al.  Neoadjuvant chemotherapy in 126 operable breast cancers. , 1992, European journal of cancer.

[13]  M. Tubiana-Hulin,et al.  Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short‐term follow‐up , 1992, Cancer.

[14]  B. Asselain,et al.  Neoadjuvant chemotherapy in operable breast cancer. , 1991, European journal of cancer.

[15]  L. Ferrari,et al.  Changes in cell kinetics induced by primary chemotherapy in breast cancer , 1991, International journal of cancer.

[16]  R. Coombes,et al.  Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study). , 1991, British Journal of Cancer.

[17]  A. Luini,et al.  Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. , 1990, Journal of the National Cancer Institute.

[18]  C. Jacquillat,et al.  Results of neoadjuvant chemotherapy and radiation therapy in the breast‐conserving treatment of 250 patients with all stages of infiltrative breast cancer , 1990, Cancer.

[19]  K. Cowan,et al.  Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines. , 1989, Cancer communications.

[20]  G. Hortobagyi,et al.  Pathological assessment of response to induction chemotherapy in breast cancer. , 1986, Cancer research.

[21]  R. Livingston,et al.  Aggressive adriamycin‐containing regimen (PM‐FAC) in estrogen receptor‐negative disseminated breast cancer. Results of a southwest oncology group trial , 1985, Cancer.

[22]  R. Livingston.  Breast cancer and response to chemotherapy: a possible relationship of hormone receptors and doxorubicin. , 1982, Cancer treatment reviews.

[23]  B Drewinko,et al.  Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. , 1981, Cancer research.

[24]  B. Runnebaum,et al.  In vitro adriamycin sensitivity test and hormonal receptors in primary breast cancer. , 1980, European journal of cancer.

[25]  M. Daidone,et al.  Relationship between proliferative activity and estrogen receptors in breast cancer , 1979, Cancer.

[26]  R. Weichselbaum,et al.  Proliferation Kinetics of a Human Breast Cancer Line in Vitro following Treatment with 17β-Estradiol and 1-β-d-Arabinofuranosylcytosine , 1978 .

[27]  I. Tannock,et al.  Cell kinetics and chemotherapy: a critical review. , 1978, Cancer treatment reports.

[28]  J. Meyer,et al.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication , 1977, Cancer.